161 related articles for article (PubMed ID: 31443119)
1. Safety of intravenous immune globulin in an outpatient setting for patients with neuromuscular disease.
Waheed W; Ayer GA; Jadoo CL; Badger GJ; Aboukhatwa M; Brannagan TH; Tandan R
Muscle Nerve; 2019 Nov; 60(5):528-537. PubMed ID: 31443119
[TBL] [Abstract][Full Text] [Related]
2. Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease.
Lozeron P; Not A; Theaudin M; Denier C; Masnou P; Sarov M; Adam C; Cauquil C; Adams D
Muscle Nerve; 2016 May; 53(5):683-9. PubMed ID: 26467654
[TBL] [Abstract][Full Text] [Related]
3. Treatment of autoimmune neuromuscular diseases with high-dose intravenous immune globulin.
Soueidan SA; Dalakas MC
Pediatr Res; 1993 Jan; 33(1 Suppl):S95-100. PubMed ID: 8433882
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy.
Donofrio PD; Bril V; Dalakas MC; Deng C; Hanna K; Hartung HP; Hughes R; Latov N; Merkies I; van Doorn P;
Arch Neurol; 2010 Sep; 67(9):1082-8. PubMed ID: 20837852
[TBL] [Abstract][Full Text] [Related]
5. Updated consensus statement: Intravenous immunoglobulin in the treatment of neuromuscular disorders report of the AANEM ad hoc committee.
Tavee J; Brannagan TH; Lenihan MW; Muppidi S; Kellermeyer L; D Donofrio P;
Muscle Nerve; 2023 Oct; 68(4):356-374. PubMed ID: 37432872
[TBL] [Abstract][Full Text] [Related]
6. Identification and comparison of adverse events for preparations of IVIG in patients with neuromuscular diseases.
Nadeau JO; Bhibhatbhan A; McDougall D; Toth C
Clin Neurol Neurosurg; 2010 Jul; 112(6):467-9. PubMed ID: 20227821
[TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulin use for neurologic diseases.
Koski CL; Patterson JV
J Infus Nurs; 2006; 29(3 Suppl):S21-8. PubMed ID: 16878852
[TBL] [Abstract][Full Text] [Related]
8. Variability in intravenous immunoglobulin G regimens for autoimmune neuromuscular disorders.
Broyles R; Rodden L; Riley P; Berger M
Postgrad Med; 2013 Mar; 125(2):65-72. PubMed ID: 23816772
[TBL] [Abstract][Full Text] [Related]
9. Drug induced aseptic meningitis caused by intravenous immunoglobulin therapy.
Mullane D; Williams L; Merwick A; Tobin WO; McGuigan C
Ir Med J; 2012 Jun; 105(6):182-3. PubMed ID: 22973657
[TBL] [Abstract][Full Text] [Related]
10. IVIG Versus PLEX in the Treatment of Worsening Myasthenia Gravis: What is the Evidence?: A Critically Appraised Topic.
Dhawan PS; Goodman BP; Harper CM; Bosch PE; Hoffman-Snyder CR; Wellik KE; Wingerchuk DM; Demaerschalk BM
Neurologist; 2015 May; 19(5):145-8. PubMed ID: 25970838
[TBL] [Abstract][Full Text] [Related]
11. [Intravenous immunoglobulin-induced eczematous eruption in autoimmune neuromuscular diseases].
Hatake S; Shimizu F; Honda M; Takahashi S; Koga M; Kimura K; Kanda T
Rinsho Shinkeigaku; 2022 Apr; 62(4):267-271. PubMed ID: 35354723
[TBL] [Abstract][Full Text] [Related]
12. Current treatment of neuromuscular diseases.
Kokontis L; Gutmann L
Arch Neurol; 2000 Jul; 57(7):939-43. PubMed ID: 10891975
[No Abstract] [Full Text] [Related]
13. A Retrospective Observational Study of Adverse Reactions Associated With Intravenous Immunoglobulin Infusion.
Kato H; Hayashi M; Ohashi W; Yamaguchi T; Tanaka S; Kozono A; Gao S; Katai A; Niwa R; Matsuo T; Ishiyama K; Ando T; Ogawa M; Nakayama T
Front Immunol; 2021; 12():740517. PubMed ID: 34603326
[TBL] [Abstract][Full Text] [Related]
14. Thromboembolic complications following intravenous immunoglobulin therapy in immune-mediated neurological disorders.
Chun W; Kim Y; Park SH; Choi SJ
J Clin Neurosci; 2021 Aug; 90():311-316. PubMed ID: 34275568
[TBL] [Abstract][Full Text] [Related]
15. Intravenous immune globulin in myasthenia gravis.
Gajdos P
Clin Exp Immunol; 1994 Jul; 97 Suppl 1(Suppl 1):49-51. PubMed ID: 8033435
[TBL] [Abstract][Full Text] [Related]
16. Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: Systematic review.
Johansen A; Christensen SJ; Scheie D; Højgaard JLS; Kondziella D
Neurology; 2019 Apr; 92(14):663-674. PubMed ID: 30850443
[TBL] [Abstract][Full Text] [Related]
17. Home IVIG for CIDP: a focus on patient centred care.
Katzberg HD; Rasutis V; Bril V
Can J Neurol Sci; 2013 May; 40(3):384-8. PubMed ID: 23603176
[TBL] [Abstract][Full Text] [Related]
18. Intravenous immunoglobulin therapy for neuromuscular disorders.
Ross MA
Semin Neurol; 2007 Sep; 27(4):340-6. PubMed ID: 17701871
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of therapeutic options used for myasthenia gravis.
Mandawat A; Kaminski HJ; Cutter G; Katirji B; Alshekhlee A
Ann Neurol; 2010 Dec; 68(6):797-805. PubMed ID: 21061395
[TBL] [Abstract][Full Text] [Related]
20. A Case of IVIG-Induced Aseptic Chemical Meningitis.
Patel A; Potu KC; Sturm T
S D Med; 2017 Mar; 70(3):119-121. PubMed ID: 28813773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
